Amyloid PET imaging: Standardization and integration with other Alzheimer’s disease biomarkers

Silvia Morbelli, Matteo Bauckneht

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Amyloid plaques are a neuropathologic hallmark of Alzheimer’s disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET). Several radiotracers for amyloid PET have been investigated, including 11C-Pittsburgh compound B and the 18F-labeled compounds such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol. Besides the injected radiotracer, images can be interpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and analytical methods.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages203-212
Number of pages10
DOIs
Publication statusPublished - Jan 1 2018

Publication series

NameMethods in Molecular Biology
Volume1750
ISSN (Print)1064-3745

Keywords

  • Alzheimer’s disease
  • Amyloid PET
  • Biomarkers
  • Brain

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Amyloid PET imaging: Standardization and integration with other Alzheimer’s disease biomarkers'. Together they form a unique fingerprint.

Cite this